Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

Basit Öğe Kaydı
dc.authoridFatma Paksoy Türköz / 0000-0002-2314-263Xen_US
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorscopusidFatma Paksoy Türköz / 36560519600
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.authorwosidFatma Paksoy Türköz / ABF-9350-2020
dc.contributor.authorTural, Deniz
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorSümbül, ahmet Taner
dc.contributor.authorÖzhan, Nail
dc.contributor.authorÇakar, Burcu
dc.contributor.authorPaksoy Türköz, Fatma
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2021-05-25T11:07:17Z
dc.date.available2021-05-25T11:07:17Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab was modest. In the current study, we evaluated the pretreatment prognostic factors for overall survival in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy in the Expanded-Access Program of Atezolizumab. Patients and methods: In this study, we present a retrospective analysis of 113 patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy. Data of the patients was obtained from patient files and hospital records. Eligible patients included metastatic urothelial carcinoma patients treated with at least one course of ATZ. Univariate analysis was used to identify clinical and laboratory factors that significantly impact OS. Variables were retained for multivariate analysis if they had a statistical relationship with OS (p < 0.1), and then included a final model of p < 0.05. Results: The median follow-up duration was 23.5 months. Of the patients, 98 (86.7%) were male and 13.3% were female. The median age was 65 years of age (37-86). In univariate analysis, primary tumor location in the upper tract, increasing absolute neutrophil count (ANC), increasing absolute lymphocyte count, neutrophil-to-lymphocyte ratio (NLR) > 3, liver metastases, baseline creatinine clearance less (GFR) than 60 ml/min, Eastern Cooperative Oncology Group (ECOG) performance status (1 ?), and hemoglobin levels below 10 mg/dl were all the significantly associated with OS. Three of the five adverse prognostic factors according to the Bellmunt criteria were independent of short survival: liver metastases HR 3.105; 95% CI 1.673-5.761; p < (0.001), ECOG PS (1 ?) HR 2.184; 95% CI 1.120-4.256; p = 0.022, and Hemoglobin level below 10 mg/dl HR 2.680; 95% CI 1.558-4.608; p < (0.001). In addition, NLR > 3 hazard ratio [HR] 2.092; 95% CI 1.031-4.243; p = 0.041 and GFR less than 60 ml/min HR 1.829; 95% CI 1.1-3.041; p = 0.02, maintained a significant association with OS in multivariate analysis. Conclusions: This model confirms the Bellmunt model with the addition of NLR > 3 and GFR less than 60 ml/min and can be associated with clinical trials that use immunotherapy in patients with bladder cancer.en_US
dc.identifier.citationTural, D., Ölmez, Ö. F., Sümbül, A. T., Özhan, N., Çakar, B., Köstek, O., Ekenel, M., Erman, M., Coşkun, H. Ş., Selçukbiricik, F., Keskin, Ö., Türköz, F. P., Oruç, K., Bayram, S., Bilgetekin, İ., Yıldız, B., Şendur, M., Paksoy, N., Dirican, A., Erdem, D., … Artaç, M. (2021). Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. International journal of clinical oncology, 10.1007/s10147-021-01936-6. Advance online publication. https://doi.org/10.1007/s10147-021-01936-6en_US
dc.identifier.doi10.1007/s10147-021-01936-6en_US
dc.identifier.pmid34023933en_US
dc.identifier.scopus2-s2.0-85106432319en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1007/s10147-021-01936-6
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1752
dc.identifier.wosWOS:000653022600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorPaksoy Türköz, Fatma
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Journal of Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtezolizumaben_US
dc.subjectBladder Canceren_US
dc.subjectImmunotherapyen_US
dc.subjectUrothelial Carcinomaen_US
dc.titlePrognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumaben_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
54.pdf
Boyut:
3.83 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu